Nonalcoholic steatohepatitis (NASH) is a growing global health concern, with no FDA-approved treatments currently available. However, the push for effective NASH therapeutics is driving significant research and investment. Pharmaceutical companies are actively developing therapies targeting fibrosis, inflammation, and metabolic dysfunction, shaping the landscape of the NASH pipeline.
Leading...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek